A newly discovered small molecule with broad reactivity against diverse HIV-1 strains prevents the surface envelope glycoprotein from fusing with host cells and offers a potential new anti–HIV-1 target.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Herschhorn, A. et al. Nat. Chem. Biol. 10, 845–852 (2014).
US Food and Drug Administration, Antiretroviral drugs used in the treatement of HIV infection. FDA, http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm118915.htm (2014).
Julien, J.P. et al. Science 342, 1477–1483 (2013).
Krauskopf, L. & Richwine, L. Pfizer wins U.S. approval for new HIV drug. Reuters, http://www.reuters.com/article/2007/08/06/businesspro-pfizer-hiv-dc-idUSN0642522320070806 (2007).
Thaczuk, D. & Hosein, S.R. T-20 (enfuvirtide, Fuzeon). CATIE, http://www.catie.ca/fact-sheets/fusion-inhibitors/t-20-enfuvirtide-fuzeon (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ward, A. Viral fusion arrested. Nat Chem Biol 10, 797–798 (2014). https://doi.org/10.1038/nchembio.1632
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1632